Partner News
The section includes updates from partner organizations on related advocacy efforts.
Materials in this section
Innovations in HCV Diagnostics: Real-World Implementation - 4 Key Takeaways
Virtual satellite session at 2021 International Conference on Health and Hepatitis Care in Substance Users, chaired by Treatment Action Group, The Kirby Institute, UNSW Sydney, FIND, and INPUD. More
Three Additional Generic Manufacturing Partners Join Efforts to Increase Access to Generic Hepatitis C Treatment Glecaprevir/Pibrentasvir
The Medicines Patent Pool signed three new sublicence agreements with generic companies to develop, manufacture and supply high-quality affordable versions of glecaprevir/pibrentasvir. More
Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C
The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More
Have a Heart, Save My Liver! Who Has Access to the Cure in Africa?
TAG’s HCV Community Engagement Officer presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. More
First Hepatitis C Treatment Developed Through South-South Cooperation Registered in Malaysia
New treatment combination for hepatitis C virus is an additional affordable option for millions still waiting for access to lifesaving treatments in middle-income countries. More
Russia Stuns UN High-Level Meeting on AIDS by Refusing to Support Consensus Declaration
Russia proposed last-minute oral amendments to the meeting’s final declaration – removing references to “rights”; the decriminalization of sex work; and harm reduction in the context of HIV response. More
Call for Applications! Malaria, Hepatitis C, and Latent TB Infection Long-Acting Technologies Community Advisory Board
TAG and AfroCAB are excited to share a call for a new cross-disease long-acting technologies CAB focused on malaria, hepatitis C, and latent TB infection. Apply now! Deadline: 21 May 2021. More
Migrants’ Inclusion Central to Achieving HIV and Hepatitis C Targets by 2030
In July 2018, EATAN, in partnership with TAG and other migrant-focused organizations, hosted the first European African HIV & HCV Community Summit. More
Hepatitis C among People Who Use Drugs
61st CND side event (March 2018)
A side event, organized during the 61st CND, aimed at raising the profile of viral hepatitis as a major health issue and promoting harm reduction and drug policy reform. More
APN+ Joins MTAAG+ in Congratulating Malaysia on Sofosbuvir Compulsory License
Compulsory license ends Gilead’s dangerous games with lives of hepatitis C patients in Malaysia; Result of hard fought efforts of community-based groups, NGOs and treatment providers. More
